KLK3 and cancer: To improve sensitivity, clinical guidelines3 recently recommended reducing the PSA cutoff to 2.5 ng/ml rather than the traditional threshold of 4.0 ng/mL because the latter has a sensitivity of 67–80%, which implies that some cancers are missed with the conventional cutoff4.